In the spotlight: a novel CD37 antibody-drug conjugate.
In this issue of Blood, Deckert et al make a strong argument in favor of IMGN529, a novel anti-CD37 maytansinoid antibody-drug conjugate (ADC), elegantly showing its activity against B-cell lymphoma in in vitro and in vivo preclinical studies.
MEMORIAL SLOAN-KETTERING CANCER CENTER.
M Lia
ML
Palomba
Anas
A
Younes
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001402:B-Lymphocytes / Q000187:drug effects*; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D008453:Maytansine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D059470:Tetraspanins / Q000276:immunology*
D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000951:Antigens, Neoplasm; C059071:CD37 protein, human; D000922:Immunotoxins; D059470:Tetraspanins; D008453:Maytansine; C585625:naratuximab emtansine